Price T Rowe Associates Inc Erasca, Inc. Transaction History
Price T Rowe Associates Inc
- $935 Billion
- Q3 2025
A detailed history of Price T Rowe Associates Inc transactions in Erasca, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 93,580 shares of ERAS stock, worth $241,436. This represents 0.0% of its overall portfolio holdings.
Number of Shares
93,580
Previous 86,468
8.23%
Holding current value
$241,436
Previous $110,000
86.36%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding ERAS
# of Institutions
156Shares Held
213MCall Options Held
281KPut Options Held
32K-
Frazier Life Sciences Management, L.P. Menlo Park, CA22.7MShares$58.6 Million2.1% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD20.2MShares$52.2 Million0.03% of portfolio
-
Vr Adviser, LLC New York, NY17.9MShares$46.1 Million5.91% of portfolio
-
Logos Global Management LP San Francisco, CA15.2MShares$39.1 Million3.82% of portfolio
-
Suvretta Capital Management, LLC New York, NY14.5MShares$37.4 Million0.95% of portfolio
About Erasca, Inc.
- Ticker ERAS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 122,147,000
- Market Cap $315M
- Description
- Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...